Several lines of evidence suggest a critical role of COX-2 expression in ischemic stroke, atherosclerosis and cancer, and selective COX-2 inhibitors may represent novel chemopreventive tools [38,39]. This evidence concerns the gene PTGS2 and atherosclerosis.